Articles Vol. 66 No. 4 25/07/2025

15. EVALUATION OF ACUTE AND SUBCHRONIC TOXICITY OF TĐĐ-HV HARD CAPSULE EXTRACT IN EXPERIMENTAL ANIMALS.

Nguyen Trung Nghia1,2, Pham Viet Hoang3,4, Le Huyen Trang5,6, Lu Doan Hoat Muoi3,4, Le Nguyen Long1,2, Le Ngoc Bich Son7,8, Nguyen Thi Nhu Quynh9,10
1 National Hospital of Tropical Diseases
2 Bệnh viện Nhiệt đới Trung ương
3 Viet Nam University Of Traditional Medicine
4 Học viện Y Dược học Cổ truyền Việt Nam
5 Viet Nhat traditional medicine clinic
6 Phòng khám chuyên khoa Việt Nhật
7 Tranditional Medicine Administration
8 Cục quản lý Y dược cổ truyền
9 Faculty of Medicine - Hanoi University of Business and Technology
10 Khoa Y-Đại học Kinh doanh và Công nghệ Hà Nội
Corresponding author: dr.quynh90@gmail.com
DOI: 10.52163/yhc.v66i4.2877
18 Views
16 Downloads
Keywords
Hard capsules TĐĐ-HV toxicity experimental diabetes mellitus
Abstract

 

Objective: To evaluate the acute and sub-chronic toxicity of TĐĐ-HV hard capsules in experimental animals.

Methods: The oral acute toxicity was studied in Swiss mice using the Litchfield–Wilcoxon method. The oral sub-chronic toxicity was assessed in Wistar rats, following the guidelines of the WHO and the Ministry of Health.

Results: The LD50 of TĐĐ-HV hard capsules could not be determined and no acute toxicity manifestations were observed in orally administered mice at doses equivalent to 20.83 times the anticipated human therapeutic dose (corresponding to 15.75 g extract/day). Subchronic toxicity: rats administered doses of 378 mg/kg/day and 1134 mg/kg/day showed no statistically significant differences in general condition, hematological, gross anatomical observations, biochemical and histological indices of liver and kidney between control group and 2 groups using drug had no difference (p > 0.05).

Conclusion: TĐĐ-HV hard capsules extract does not cause acute toxicity; and is safe at the dose levels used in the 28-day subchronic toxicity evaluation in experimental animals.

References
[1]
Fonseca VA (2009) Defining and Characterizing the Progression of Type 2 Diabetes, American Diabetes Assocation, pp. 151- 155 Google Scholar
[2]
David R.Whiting, et al (2011) IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030, Diabetes Research Clinical Pratice. 10, pp. 311-321 Google Scholar
[3]
Đỗ Tất Lợi (2015), Cây thuốc và vị thuốc Việt Nam. Google Scholar
[4]
World Health Organization (2013), Working group on the safety and efficacy of herbal medicine, Report of regional office for the western pacific of the World Health Organization Google Scholar
[5]
Cục Khoa học công nghệ và đào tạo, Bộ Y tế (2015), Quyết định về việc ban hành tài liệu chuyên môn “Hướng dẫn thử nghiệm tiền lâm sàng và lâm sàng thuốc đông y, thuốc từ dược liệu”, Quyết định số 141/QĐ-K2ĐT ngày 27 tháng 11 năm 2015. Google Scholar
[6]
Bộ Y Tế, “Dược điển Việt Nam V, tập 2,” NXB Y học, 2019 Google Scholar